We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The company has installed the software in large healthcare systems to manage disease areas, such as inflammatory bowel diseases, epilepsy, rheumatology and ovarian cancer. Read More
Micro C works with the company’s OXOS Platform for image management, telehealth collaboration and delivery of artificial intelligence-based diagnostics. Read More
The test has demonstrated 98 percent sensitivity in identifying positive samples and 100 percent specificity in identifying negative samples. Read More
The FDA’s Breakthrough Device designation is intended to give patients more timely access to new devices by expediting their development and review. Read More